Minimed Group raises 2027 organic revenue outlook after Q1 growth

On Tuesday, Minimed Group (NASDAQ: MMED ) discussed first-quarter financial results during its earnings call.

The full transcript is provided below.

This content is powered APIs.

For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Minimed Group reported a strong start to fiscal year 2027 with organic revenue growth of 16%, driven by the U.S. launch of MiniMed Flex and international expansion.

The company advanced four pipeline programs and highlighted the upcoming launch of MiniMed Fit and Vivera, a fully closed-loop algorithm, both expected in calendar year 2027.

Q1 revenue was $843 million, with U.S. growth at 13% and international growth at 16.9%.

Adjusted EBITDA was $83 million with a margin of 9.9%, impacted by accelerated investments and FX charges.

Management raised fiscal 2027 organic revenue growth outlook to 10.5% and reaffirmed adjusted EBITDA margin guidance of 16% for the year.

The company is making progress on exiting transition service agreements with Medtronic and expects improvements in cash generation as these activities roll off.

Full Transcript OPERATOR Good day and welcome to Minimed Group's first quarter and fiscal year 2027 earnings webcast.

At this time, all participants are in a listen-only mode.

After the speaker's presentation there will be a question-and-answer session.

Instructions will follow at that time.

Today's call is being recorded.

I will now hand the conference over to your speaker host, Ryan Weisspenning, VP of Investor Relations.

Please go ahead.

Ryan Weisspenning, Vice President and Head of Minimed Group Investor Relations Hello everyone and thanks for joining us today for our fiscal 27 first quarter earnings webcast.

I'm Ryan Weisspenning, Vice President and Head of Minimed Group Investor Relations.

Joining me today are Que Dallara, Chief Executive Officer, and Chad Spooner, Chief Financial Officer.

Today's program will last no longer than 45 minutes so that we may complete the call before the market opens.

Earlier this morning we issued a press release discussing our results and containing several financial schedules.

We also posted an earnings presentation that provides additional details on our performance.

Both can be accessed on our website at investors.minimed.com.

During today's program, many of the statements we make may be considered forward-looking statements, which are subject to risks and uncertainties, and actual results may differ materially from those projected in any forward-looking statement.

Please take a moment to review the cautionary statements regarding forward-looking statements included in our earnings press release and the presentation.

Additional information concerning factors that could cause our actual results to differ is contained in the periodic reports and other filings we make with the SEC.

Forward-looking statements speak only as of the date they are made, and we do not undertake to update any forward-looking statement or any of the information contained in today's program.

In today's program, unless we say otherwise, all comparisons are made on a year-over-year basis, and references to revenue growth are to organic revenue growth, a non-GAAP financial measure.

A reconciliation of organic revenue growth to the most directly comparable GAAP financial measure is included in today's earnings press release.

With our organic revenue growth and adjusted EBITDA margin guidance, we do not provide reconciliations to the comparable GAAP measures because certain items in these forward-looking non-GAAP measures cannot be predicted without unreasonable effort.

We operated as part of Medtronic until our IPO in early March, so our GAAP financial statements for historical periods were prepared on a carve-out basis and include certain historical cost allocations from Medtronic for centralized support functions.

On today's program, unless we say otherwise, year-over-year and sequential comparisons of P&L line items will be made to historical period financials that are presented on an adjusted standalone basis, which replaced historical Medtronic cost allocations with the expected run-rate cost structure for standalone Minimed Group.

This information also eliminated the impact of certain incremental nonrecurring costs.

These standalone P&L items are non-GAAP financial measures and are included to provide consistency and comparability while evaluating operational performance on a run-rate standalone basis for reporting periods after Minimed Group's fiscal year 2026.

A reconciliation of these standalone non-GAAP financial measures to their most directly comparable GAAP financial measures is included in today's earnings presentation.

With that, over to you, Que.